
AKVA group ASA: Q3 2023 financial reporting
Acceptable activity level and profitability in Sea Based but challenging post smolt market in Norway
AKVA group delivered revenue for Q3 of MNOK 817 (840), a decrease of 3% compared to Q3 2022.
EBITDA increased from MNOK 25 in Q3 2022 to MNOK 78 in Q3 2023.
Order intake of MNOK 600 (650) in Q3 and order backlog of BNOK 2,6 at the end of September 2023.
Acquisition of 51% of the shares in Submerged AS was completed in Q3 with the option to increase the ownership to 100% in 2028 based on certain conditions
Ownership in Newfoundland Aqua Service Ltd was increased from 70% to 98,5% in October through execution of option
A rightsizing process, targeting MNOK 45 in annual cost savings, will be carried out in Q4 to adapt the organization to the current and expected activity level
Due to change in market conditions AKVA will revise the medium-term financial targets during Q4
The activity in the first three quarters of 2023 were somewhat higher compared to last year. Overall, the order intake was sound with the award of RAS contract for Nordic Aqua Partners (MEUR 40) and the post smolt contract for Cermaq Norway (minimum MEUR 60) as the largest contracts. However, the introduction of the resource tax has a negative impact on the activity level both in Land Based and parts of the Sea Based business, and the market outlook is challenging and uncertain. Profitability is continuing to improve compared to last year but is still below expectations. The Land Based business segment is still impacted by a high cost base compared to current activity level and by lower profitability in parts of the project portfolio. The profitability in the Sea Based business segment is acceptable with a healthy product mix supported by the commercial breakthrough of deep farming concepts.
Due to change in market conditions a rightsizing process, targeting MNOK 45 in annual cost savings, will be executed during Q4 to adapt the organization to the current and expected activity level.
Sea Based Technology (SBT)
SBT revenue for Q3 2023 ended at MNOK 660 (681). EBITDA and EBIT for the segment in Q3 ended at MNOK 79 (79) and MNOK 41 (44), respectively. The related EBITDA and EBIT margins were 11.9% (11.5%) and 6.3% (6.4%), respectively.
Order intake in Q3 2023 was MNOK 574 compared to MNOK 450 in Q3 2022. Order backlog ended at MNOK 731 compared to MNOK 672 last year.
The Nordic region experienced an increase in revenue from MNOK 417 in Q3 2022 to MNOK 381 in Q3 2023.
In the Americas region, the revenue was MNOK 171, which is a decrease from 186 MNOK in the third quarter last year.
Europe and Middle East (EME) had a revenue of MNOK 73 in Q3 2023, compared to the revenue of MNOK 114 in the third quarter last year.
Land Based Technology (LBT)
Revenues for the third quarter were MNOK 124 (134). EBITDA and EBIT ended at MNOK -11 (-63) and MNOK -13 (-106), respectively. The related EBITDA and EBIT margins were -8.5% (-46.6%) and -10.4% (-78.9%). EBITDA and EBIT in Q3 2022 was significantly impacted by cost accruals for restructuring and cost saving programs.
Order intake in Q3 2023 of MNOK 4 compared to MNOK 167 in Q3 2022. Order backlog ended at MNOK 1,728, compared to MNOK 812 last year.
Digital (DI)
The revenue in the segment was MNOK 33 (25) in Q3 2023. EBITDA and EBIT ended at MNOK 10 (9) and MNOK 0 (3), respectively. The related EBITDA and EBIT margins were 29.9% (38.0%) and 0.8% (11.5%). The order intake was MNOK 21 (32) in the quarter.
Balance sheet
Working capital as a percentage of 12 months rolling revenue is 8.6% (5.9%). Cash and unused credit facilities amounted to MNOK 526 (793) at the end of Q3. Total assets and total equity amounted to MNOK 3,732 and MNOK 1,176 respectively, resulting in an equity ratio of 31.8% (34.0%) at the end of Q3 2023.
Dividend
The Company’s main objective is to maximize the return on the investment made by its shareholders through both increased share prices and dividend payments. The company has decided not to pay any dividend in 2023.
Order Backlog
The order backlog at the end of Q2 was MNOK 2,609 (1,579). MNOK 1,728 or 66% of total order backlog at the end of Q3 relates to Land Based Technology (LBT).
Outlook
Salmon prices expected to remain strong driven by reduced supply
The implications from the introduction of new resource tax in Norway are negative both for Land Based business and parts of Sea Based business
Measures will be taken in Q4 23 to adopt the cost base to the current and expected activity level
Due to change in market conditions AKVA will revise the medium-term financial targets during Q4
About AKVA group
AKVA group is a technology and service partner to the aquaculture industry worldwide. The company has 1 410 employees, offices in 11 countries and had a total turnover of NOK 3.4 billion in 2022. We are a public listed company operating in one of the world’s fastest growing industries and supply everything from single components to complete installations, both for sea farming and land based aquaculture. AKVA group is recognized as a pioneer and technology leader through more than 40 years.
Dated: 10 November 2023
AKVA group ASA
Web: www.akvagroup.com
CONTACTS:
Knut Nesse | Chief Executive Officer |
Phone: | +47 51 77 85 00 |
Mobile: | +47 91 37 62 20 |
E-mail: | knesse@akvagroup.com |
Rony Meinkøhn | Chief Financial Officer |
Phone: | +47 51 77 85 00 |
Mobile: | +47 98 20 67 76 |
E-mail: | rmeinkohn@akvagroup.com |
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Avance Gas Holding Ltd: Ex Dividend USD 0.50 today7.12.2023 07:01:00 CET | Press release
Hamilton, Bermuda, December 7, 2023 The shares in Avance Gas Holding Ltd (ticker: "AGAS") will be traded ex-dividend USD 0.50 as of today relating to the dividend for the third quarter of 2023. The dividend will be paid on December 15, 2023. For further information, please contact: Randi Navdal Bekkelund - Chief Financial Officer Tel: +47 23 11 40 00 Email: IR@avancegas.com ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGCs) and operates a fleet of fourteen modern ships including two dual fuel LPG newbuildings for delivery in early 2024 as well as four medium sized gas/ammonia carriers due for delivery in 2025 and 2026. For more information about Avance Gas, please visit www.avancegas.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook7.12.2023 07:00:00 CET | Press release
PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms, as well as a robust balance sheet and an external-innovation strategy yielding compelling results. Ipsen is now ready for its next phase of growth with several launches across multiple potential indications, providing more options for patients with high unmet medical needs. Our journey will be driven by the combination of the growth platforms, our new medicines and more external-innovation transactions to come. We will also continue to deliver on our ambitious sustainability objectives and road
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC7.12.2023 07:00:00 CET | Press release
New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual peroxisome activated receptor alpha/delta (PPAR α,δ) agonist, investigational elafibranor could potentially be the first novel second-line treatment for the rare, cholestatic liver disease, PBC, in nearly a decade. The target FDA PDUFA date under priority review is June 10, 2024. The European Medicines Agency (EMA) has also validated Ipsen’s Marketing Authorization Applica
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage7.12.2023 07:00:00 CET | Press release
Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commission. In a staged roll-out across the key European markets, launches will follow in the UK and France later that year, with Spain and Italy scheduled to launch in early 2025,” said Dario Eklund, CEO of Santhera. “With Geert Jan and Marc joining the Executive Committee, we are leveraging the existing expertise within our leadership team and are elevating the commercial and supply chain functions to their level of importance as we enter the commercial market.” Geert Jan van Daal, MD, PhD, has held v
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology7.12.2023 03:30:00 CET | Press release
R&D Day Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology Details strong pipeline including Sanofi’s record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product’ assets with a potential of over €5 billion peak sales Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapiesEnhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 yearsAmbition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of